Compare H & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | H | GH |
|---|---|---|
| Founded | 1957 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6B | 13.3B |
| IPO Year | 2009 | 2018 |
| Metric | H | GH |
|---|---|---|
| Price | $164.37 | $88.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 19 |
| Target Price | ★ $179.53 | $119.79 |
| AVG Volume (30 Days) | 676.7K | ★ 2.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.37% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,685,000,000.00 | $982,021,000.00 |
| Revenue This Year | $110.63 | $33.30 |
| Revenue Next Year | $7.01 | $28.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 5.78 | ★ 32.88 |
| 52 Week Low | $108.24 | $36.36 |
| 52 Week High | $180.53 | $120.74 |
| Indicator | H | GH |
|---|---|---|
| Relative Strength Index (RSI) | 58.13 | 49.73 |
| Support Level | $137.21 | $82.33 |
| Resistance Level | $171.80 | $90.28 |
| Average True Range (ATR) | 5.39 | 5.35 |
| MACD | 0.69 | 0.50 |
| Stochastic Oscillator | 55.54 | 58.65 |
Hyatt is an operator of owned (2% of total rooms) and managed and franchised (98%) properties across about 35 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 45% for the US, 31% rest of world, and 24% Asia-Pacific.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.